Bayrab Related Published Studies
Well-designed clinical trials related to Bayrab (Rabies Immune Globulin)
Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis. [2011.03.24]
Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. [2010.08.16]
Equivalence between pre-exposure schemes for human rabies and evaluation of the need for serological monitoring. [2010.06]
Immunogenicity and safety study of Indirab: a Vero cell based chromatographically purified human rabies vaccine. [2010.05.28]
A comparative study on the safety and immunogenicity of Purified duck embryo vaccine [corrected] (PDEV, Vaxirab) with purified chick embryo cell vaccine (PCEC, Rabipur) and purifed vero cell rabies vaccine (PVRV, Verorab). [2009.12.10]
[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India] [2009.10]
[Safety and immunogenicity of rabies vaccine (chick embryo cell) for human use produced in Germany and India]. [2009.10]
A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. [2009.04]
Comparison of antibody responses after vaccination with two inactivated rabies vaccines. [2009.01.13]
Efficiency of Matricaria chamomilla CH12 and number of doses of rabies vaccine on the humoral immune response in cattle. [2008.12]
First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. [2008.11.05]
Protecting Indian schoolchildren against rabies: pre-exposure vaccination with purified chick embryo cell vaccine (PCECV) or purified verocell rabies vaccine (PVRV). [2008.09]
Intradermal DNA vaccination in ear pinnae is an efficient route to protect cats against rabies virus. [2008.03]
BHK-21 cell culture rabies vaccine: immunogenicity of a candidate vaccine for humans. [2008]
One or three intradermal injections within one week for rabies pre-exposure immunization. [2008]
Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium. [2007.11.23]
Immunogenicity study of abbreviated rabies preexposure vaccination schedules. [2007.05]
Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. [2006.05.08]
Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine. [2005.06.10]
Safety and immunogenicity of a new chromatographically purified rabies vaccine in comparison to the human diploid cell vaccine. [2004.07]
Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. [2004.04.01]
[Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab) in pre-exposure prophylaxis in humans] [2004.01]
Immunogenicity and efficacy of Fermi-type nerve tissue rabies vaccine in mice and in humans undergoing post-exposure prophylaxis for rabies in Ethiopia. [2001.10]
Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. [2001.09.14]
The role of vitamin A in enhancing humoral immunity produced by antirabies vaccine. [2001.07]
Immunogenicity and effectiveness of post-exposure rabies prophylaxis with a new chromatographically purified Vero-cell rabies vaccine (CPRV): a two-stage randomised clinical trial in the Philippines. [2000.02.25]
Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. [2000]
Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination. [1999.12]
An experimental study on the endurance of immunologic memory of intradermal micro-injection with rabies vaccine and boosting immune effect. [1999.08]
A new Vero cell rabies vaccine: results of a comparative trial with human diploid cell rabies vaccine in children. [1999.07]
Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial. [1999.03]
Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. [1998.11]
Safety and efficacy of purified Vero cell rabies vaccine given intramuscularly and intradermally. (Results of a prospective randomized trial). [1998.10]
Evaluation of the safety, immunogenicity, and pharmacokinetic profile of a new, highly purified, heat-treated equine rabies immunoglobulin, administered either alone or in association with a purified, Vero-cell rabies vaccine. [1998.07.30]
Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. [1998.03]
Randomised feasibility trial of pre-exposure rabies vaccination with DTP-IPV in infants. [1997.06.07]
Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. [1997.04]
[Serological effect after immunization with rabies vaccine of different doses] [1996.06]
A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. [1994.05]
[Pre-exposure rabies immunization in occupational exposed milieu. A 5-year prospective and comparative study of immunogenicity] [1993.04.03]
Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. [1992.11]
Immunisation with canarypox virus expressing rabies glycoprotein. [1992.06.13]
[Comparison of PVRV and HDCV rabies vaccines as to immunity, reliability and protective value] [1992.01]
What happens if intradermal injections of rabies vaccine are partially or entirely injected subcutaneously? [1990]
Two-year comparative trial on the immunogenicity and adverse effects of purified chick embryo cell rabies vaccine for pre-exposure immunization. [1989.10]
Human diploid cell rabies vaccine purified by zonal centrifugation: a controlled study of antibody response and side effects following primary and booster pre-exposure immunizations. [1989.10]
Immunoenhancement with combined rabies and aluminium-adjuvanted tetanus vaccines. [1989.06]
Comparative study of two human diploid rabies vaccines administered with antirabies globulin. [1988.12]
Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. [1988.06]
Dose-response effects in immunizations with keyhole limpet haemocyanin and rabies vaccine: shift in some immunodeficiency states. [1987.11]
Pre-exposure studies with purified chick embryo cell culture rabies vaccine and human diploid cell vaccine: serological and clinical responses in man. [1987.09]
Well-designed clinical trials possibly related to Bayrab (Rabies Immune Globulin)
A field trial to assess a blood-stage malaria vaccine. [2011.09.15]
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. [2011.02]
A field trial to assess a blood-stage malaria vaccine. [2011]
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambarene, Gabon. [2010.09.24]
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial. [2010.02.04]
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results
of a phase 1 randomized controlled trial. [2010]
Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia. [2009.04]
Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial. [2009.03.26]
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. [2009]
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. [2008.12.11]
Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial. [2008.01.23]
A comparative study on the immunogenicity, safety and tolerance of purified duck embryo vaccine (PDEV) manufactured in India (Vaxirab) and Switzerland (Lyssavac-N): a randomized simulated post-exposure study in healthy volunteers. [2007.12.05]
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. [2007.01.02]
Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. [2004.02]
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. [2003.03.15]
Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. [2001.12.08]
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. [1998.05]
The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay. [1991.01]
Other research related to Bayrab (Rabies Immune Globulin)
Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab
N) administered intradermally as post exposure prophylaxis. [2014]
Making rabies prophylaxis more economical: immunogenicity and safety results from
a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. [2014]
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. [2011.10]
Evaluation of water-in-oil-in-water multiple emulsion and microemulsion as potential adjuvants for immunization with rabies antigen. [2011.08.17]
Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. [2011.08]
Rabies postexposure prophylaxis in a UK travel clinic: ten years' experience. [2011.07]
Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. [2011.06.20]
Live attenuated rabies virus co-infected with street rabies virus protects animals against rabies. [2011.06.06]
Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV). [2011.05.12]
Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. [2011.05.09]
Construction and immunogenicity of a recombinant pseudotype baculovirus expressing the glycoprotein of rabies virus in mice. [2011.05]
Rabbit anti-rabies immunoglobulins production and evaluation. [2011.04]
High-density baiting with ONRAB(R) rabies vaccine baits to control Arctic-variant rabies in striped skunks in Ontario, Canada. [2011.04]
Is the skin sensitivity test required for administering equine rabies immunoglobulin? [2011.03]
Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus. [2011.03]
Five-year (January 2004-December 2008) surveillance on animal bite and rabies vaccine utilization in the Infectious Disease Hospital, Dhaka, Bangladesh. [2011.01.29]
Immunogenicity and efficacy of two rabies vaccines in wild-caught, captive raccoons. [2011.01]
Analysis of an outbreak of human rabies in 2009 in Hanzhong District, Shaanxi province, China. [2011.01]
Rabies research in resource-poor countries. [2011]
Design of future rabies biologics and antiviral drugs. [2011]
Postexposure prophylaxis for rabies in resource-limited/poor countries. [2011]
Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human
use in post-exposure prophylaxis. [2011]
Rabies in the Eastern Cape Province of South Africa--where are we going wrong? [2010.12]
Intracerebral vaccination suppresses the spread of rabies virus in the mouse brain. [2010.12]
Socioeconomic status is a critical risk factor for human rabies post-exposure prophylaxis. [2010.10.04]
Seroconversion following incomplete human rabies postexposure prophylaxis. [2010.09.07]
Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. [2010.09]
Impact of emergency oral rabies vaccination of foxes in northeastern Italy, 28 December 2009-20 January 2010: preliminary evaluation. [2010.07.15]
Incidence of dog bite and anti-rabies vaccine utilization in the, University of Benin Teaching Hospital, Benin City, Nigeria: A 12-year assessment. [2010.07.05]
Evaluation of a commercial rabies ELISA as a replacement for serum neutralization assays as part of the pet travel scheme and oral vaccination campaigns of foxes. [2010.07]
Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis. [2010.07]
Importance of antirabies revaccination for an adequate antirabies protection in bovine newborns. [2010.07]
|